Trust and the regulation of pharmaceuticals: South Asia in a globalised world

Globalization and Health

Volumn 7, Issue , 2011, Pages

  Brhlikova, Petra ^a   Harper, Ian ^a   Jeffery, Roger ^a   Rawal, Nabin ^b   Subedi, Madhusudhan ^b   Santhosh, M R ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b TRIBHUVAN UNIVERSITY   (Nepal)

^c Centre for Trade and Development   (India)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; OXYTOCIN; RIFAMPICIN;

DRUG; GLOBALIZATION; PRIVATE SECTOR; QUALITATIVE ANALYSIS; QUALITY CONTROL; STATE ROLE; VULNERABILITY;

ARTICLE; DRUG MARKETING; DRUG RESEARCH; ETHICS; ETHNOGRAPHY; FOOD AND DRUG ADMINISTRATION; HUMAN; INDIA; INTERVIEW; NEPAL; PRIORITY JOURNAL; SOUTH ASIA; TRUST;

SOUTH ASIA;

EID: 79955415580     PISSN: None     EISSN: 17448603     Source Type: Journal    
DOI: 10.1186/1744-8603-7-10     Document Type: Article

References (60)

1. Hall M. Arrow on trust. Journal of Health Politics, Policy and Law 2001, 26:1131-1144. 10.1215/03616878-26-5-1131, 11765261.
2. Cook KS, Stepanikova I. The health care outcomes of trust: a review of empirical evidence. Researching trust and health 2008, 194-214. New York: Routledge, Brownlie J, Greene A, Howson A.
3. Parsons T. Social Structure and Dynamic Process: The Case of Modern Medical Practice. The Social System 1951, 428-479. New York: The Free Press.
4. Arrow KJ. Uncertainty and the welfare economics of medical care. The American Economic Review 1963, 53:941-973.
5. Miller J. The other side of trust in health care: prescribing drugs with the potential for abuse. Bioethics 2007, 21:51-60. 10.1111/j.1467-8519.2007.00523.x, 17845502.
6. Gilson L. Trust in health care: theoretical perspectives and research needs. Journal of Health, Organisation and Management 2006, 20:359-375.
7. Giddens A. The Consequences of Modernity. 1990, Cambridge: Polity.
8. Smith C. Understanding trust and confidence: two paradigms and their significance for health and social care. Journal of Applied Philosophy 2005, 22:299-316. 10.1111/j.1468-5930.2005.00312.x, 16453947.
9. Hosmer LT. The connecting link between organizational theory and philosophical ethics. The Academy of Management Review 1995, 20:379-403.
10. Shapiro SP. The Social Control of Impersonal Trust. American Journal of Sociology 1987, 93:623-658.
11. Jeffery R. Allopathic medicine in India: a case of de-professionalisation?. Social Science and Medicine 1977, 11:561-573.
12. Jeffery R. Recognising India's Doctors: the establishment of medical dependency, 1918-39. Modern Asian Studies 1979, 13:301-326. 10.1017/S0026749X00008337, 11620271.
13. Mechanic D. Changing medical organization and the erosion of trust. The Milbank Quarterly 1996, 74:171-189. 10.2307/3350245, 8632733.
14. Collier SJ, Ong A. Global Assemblages, Anthropological Problems. Global Assemblages: Technology, Politics and Ethics as Anthropological Problems 2005, 3-21. Malden MA, Oxford and Carlton: Blackwell, Ong A, Collier SJ.
15. Slovac P. Perceived risk, trust, and democracy. Risk Analysis 1993, 13:675-682.
16. Mishra A. The Economics of Corruption 2005, London: Oxford University Press.
17. Abraham JW. The pharmaceutical industry as a political player. The Lancet 2002, 360:1498-1501.
18. Piribo. The Pharmaceutical Market: India. 2007, London: Espicom.
19. Ernst & Young Unveiling India's Pharmaceutical Future 2005, Hyderabad: Ernst & Young, Ernst & Young.
20. Rationalizing drug distribution in India. , http://www.domain-b.com/industry/pharma/20000107drug_distribution.html
21. Francis PA. Changing Pharmacy Practices. Pharmabizcom 2006, Mumbai.
22. Jayakumar PB. Big Fish Threat to Traditional Drug Retailers. Business Standard 2007,
23. Nichter M. Paying for what ails you: Sociocultural issues influencing the ways and means of therapy payment in South India. Anthropology and International Health: South Asian Case Studies 1989, 214-231. Dordrecht: Kluwer, Nichter M.
24. last accessed on 24 June 2010., http://www.hum.au.dk/hsre/Docs/Presentations/4_Regulation-scope%20and%20limitations/1_Ashok_Kumar_Regulation.pdf
25. Kamat VR, Nichter M. Pharmacies, self-medication and pharmaceutical marketing in Bombay, India. Social Science and Medicine 1998, 47(6):779-94. 10.1016/S0277-9536(98)00134-8, 9690824.
26. Ecks S, Basu S. The Unlicensed Lives of Antidepressants in India: Generic Drugs, Unqualified Practitioners, and Floating Prescriptions. Transcultural Psychiatry 2009, 46(1):86-106. 10.1177/1363461509102289, 19293281.
27. International Narcotics Control Board Report of the International Narcotics Control Board for 2006. 2007, 120. Vienna: United Nations, 120 pp, International Narcotics Control Board.
28. Kamat VR, Nichter M. Monitoring product movement: an ethnographic study of pharmaceutical sales representatives in Bombay, India. Private Health Care Providers in Developing Countries: Serving the public interest? 1997, 124-40. Zed Books: London, S. Bennett, B. McPake, and A. Mills.
29. Oldani MJ. Thick Prescriptions: Toward an Interpretation of Pharmaceutical Sales Practices. Medical Anthropology Quarterly 2004, 18(3):325-356. 10.1525/maq.2004.18.3.325, 15484967.
30. Indian Pharmaceutical Industry: Market: Regulatory, Import and Investment Regime. , http://www.pacificbridgemedical.com/publications/html/IndiaMay2002.htm
31. PSI reports 24% jump in counterfeits. , http://www.in-pharmatechnologist.com/Industry-Drivers/PSI-reports-24-jump-in-counterfeits
32. Government of India Report of the Expert Committee on a Comprehensive Examination of Drug Regulatory Issues, Including the Problem of Spurious Drugs 2003, New Delhi: Ministry of Health and Family Welfare, Government of India.
33. World Health Organisation Counterfeit Medicines: an update on estimates. 2006, Geneva: IMPACT, World Health Organisation.
34. Commission European Report on Community Customs Activities on Counterfeit And Piracy: Results at the European Border - 2005. 2006, Brussels: Taxation and Customs Union, Commission European.
35. New counterfeit report highlights worrying trends. , http://www.in-pharmatechnologist.com/Industry-Drivers/New-counterfeit-report-highlights-worrying-trends
36. Commission European Report on Community Customs Activities on Counterfeit And Piracy: Results at the European Border - 2007. 2008, Brussels: Taxation and Customs Union, Commission European.
37. Sheth PD, Reddy MVSP, Vaidya R, Gharat M, Revikumar KG, Mondal S, Gurbani NK, Chowdary K. A Report on Challenges & Opportunities for Pharmacists in Health Care in India. 2007, New Delhi: SEARPharm Forum & WHO-India Country office.
38. CDSCO Report on Countrywide Survey for Spurious Drugs. 2009, Directorate General of Health Services, Ministry of Health & Family Welfare, Govt. of India, CDSCO., http://www.cdsco.nic.in/REPORT_BOOK_13-7-10.pdf
39. Bate R. Delhi's Fake Drug Whitewash. Wall Street Journal India 2010, last accessed on 15 February 2011., http://www.aei.org/article/102490
40. Chatterjee P. India's trade in fake drugs--bringing the counterfeiters to book. The Lancet 2001, 357:1776.
41. World Health Organisation The world medicines situation. 2004, Geneva: WHO, World Health Organisation.
42. Government Accountability Office Drug safety: Better data management and more inspections are needed to strengthen FDA's foreign drug inspection program. 2008, Washington, DC: GAO, Government Accountability Office.
43. Shankar R. US FDA opens office in Delhi, around 100 approved plants to come under vigilance. Pharmabiz 2009,
44. Drugs Manufactured at the Dewas and Paonta Sahib Facilities of Ranbaxy Laboratories, Ltd. , http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/ucm118442.htm
45. Warning Letter WL: 320-08-03. , http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2008/ucm1048134.htm
46. Warning Letter WL: 320-08-02. , http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2008/ucm1048133.htm
47. Memorandum. , http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/ucm118418.pdf
48. World Health Organization An expanded DOTS framework for effective tuberculosis control. 2002, Geneva: WHO Stop TB department, World Health Organization.
49. Bakhshi S. Tuberculosis in the United Kingdom: A Tale of Two Nations 2006, Leicester: Matador.
50. Nichter M. Global Health: Why Cultural Perceptions, Social Representations, and Biopolitics Matter 2008, Tucson: University of Arizona Press.
51. Uplekar M, Shepherd DS. Treatment of tuberculosis by private general practitioners in India. Tubercle 1991, 72(4):284-90. 10.1016/0041-3879(91)90055-W, 1811360.
52. Uplekar M, Pathania V, Raviglione M. Private practitioners and public health: weak links in tuberculosis control. The Lancet 2001, 358(9285):912-916.
53. TB Alliance Analysis of the Global TB Drug Market and Country-Specific Case Studies of TB Drug Distribution Channels. India Case Study. 2006, TB Alliance.
54. Vandan N, Ali M, Prasad R, Kuroiwa C. Physicians' Knowledge Regarding the Recommended Anti-Tuberculosis Prescribed Medication Regimen: A Cross-Sectional Survey from Lucknow, India. Southeast Asian J Trop Med Public Health 2008, 39(6):1072-75.
55. last accessed on 26 March 2011., http://www.stoptb.org/gdf/whatis/principles.asp
56. Global Drug Facility Annual Report. 2009, Geneva: World Health Organisation, Global Drug Facility.
57. last accessed on 26 March 2011., http://www.stoptb.org/assets/documents/gdf/whatis/GDF%20direct%20procurement%20service%20LOWRES.pdf
58. Mehta PB. Creating a Credible State. , http://casi.ssc.upenn.edu/iit/mehta
59. Jeffery R, Santhosh MR. The architecture of drug regulation in India: What are the Barriers to Regulatory Reform?. Journal of Health Studies 2009, 2:13-32.
60. Matsebula T, Goudge J, Gilson L. Regulating the pharmaceutical sector: Coping with low capacity while maintaining regulatory independence. 2005, London: London School of Hygiene and Tropical Medicine.